PM8002 is a next generation PD-(L)1-based bispecific that blocks the PD-L1 and VEGF pathways. By adopting PD-L1-based enrichment of the PD-L1-targeting arm, VEGF neutralization is focussed to the PD-L1+ TME to increase local efficacy and reduce off-tumour/on-target toxicity related to VEGF neutralization. By targeting these two synergistic clinically-validated targets, PM8002 can serve as a critical backbone for future combination therapies.